Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human immunodeficiency virus type 1 group-specific antigen polyprotein (HIV-1 Gag)
- Target
- HIV-1 Gag
- Molecular classification
- Viral structural protein, Polyprotein precursor, Other
01
Overview
The Human immunodeficiency virus type 1 group-specific antigen polyprotein (HIV‑1 Gag) is a large structural precursor protein essential for the formation, assembly, and infectivity of new virions. It consists of multiple domains—including matrix (MA), capsid (CA), nucleocapsid (NC), p6, and two spacer peptides—that orchestrate key steps such as binding to the plasma membrane, packaging viral RNA genomes, recruiting host factors required for budding via ESCRT machinery, and forming immature particle lattices. After budding from the host cell membrane, Gag is cleaved by the viral protease into mature components required for an infectious virus. Disruption at any stage involving this protein can block production or infectivity of new viruses[1][4][6][8].
- Other names
- Gag polyproteinGroup-specific antigen (Gag)HIV-1 Gag proteinPr55(Gag)
02
Mechanism of action
Drugs targeting this molecule would typically act by inhibiting its assembly, blocking its cleavage/maturation by the viral protease, or interfering with interactions necessary for virion formation—thus preventing production of infectious virus particles[7].
03
Biological functions
Virion assembly and buddingViral genome packagingMembrane binding and trafficking to plasma membraneRecruitment of host cell factors for viral release and maturation[1][6][7]
04
Disease associations
Infection (HIV/AIDS)
05
Safety considerations
Potential challenges include rapid emergence of drug resistance due to high mutation rates in HIV; off-target effects on host cell processes involved in vesicle trafficking; possible toxicity from disrupting normal cellular membranes.
06
Interacting drugs
Currently, no approved drugs directly target the Gag polyprotein in clinical use, but several investigational compounds and research inhibitors are being developed to interfere with its assembly or maturation. Some antiretroviral therapies indirectly affect Gag processing by inhibiting the viral protease that cleaves it into mature proteins[7].
07
Biomarkers
Levels of p24 (a major cleavage product of Gag) in blood are used as a biomarker for HIV infection and disease progression.
Beyond the preview
Go deeper on Human immunodeficiency virus type 1 group-specific antigen polyprotein (HIV-1 Gag).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human immunodeficiency virus type 1 group-specific antigen polyprotein (HIV-1 Gag).